Osimertinib (AZD9291)

別名：Mereletinib

製品コード：S7297 純度：99.99%

Osimertinib (AZD9291, Mereletinib) is an oral, irreversible, and mutant-selective EGFR inhibitor with IC50 of 12.92, 11.44 and 493.8 nM for Exon 19 deletion EGFR, L858R/T790M EGFR, and WT EGFR in LoVo cells, respectively. Phase 3.

CAS No. 1421373-65-0

サイズ	価格(税別)	在庫状況
10mM (1mL in DMSO)	JPY 29500	国内在庫あり
5mg	JPY 22000	国内在庫あり
100mg	JPY 71500	国内在庫あり
1g	JPY 220500	国内在庫あり

代表番号: 045-509-1970\|電子メール：[email protected] よく尋ねられる質問

文献中Selleckの製品使用例（393）

製品安全説明書

現在のバッチを見る：純度： 99.99%

99.99

Osimertinib (AZD9291)関連製品

関連ターゲット	EGFR/ErbB1 HER2/ErbB2 ErbB3 ErbB4 mutant EGFR	もっと見る
関連製品	AG-490 AG-1478 Canertinib (CI-1033) Rociletinib (CO-1686) WZ4002 Genistein Poziotinib PD153035 PD153035 HCl Allitinib tosylate AEE788 (NVP-AEE788) Pelitinib (EKB-569) Canertinib dihydrochloride Varlitinib Icotinib (BPI-2009H) Nazartinib (EGF816) NSC228155 PD168393 Olmutinib (BI 1482694) Zorifertinib (AZD3759) AZ5104 Lazertinib CL-387785 (EKI-785) TAK-285 Daphnetin Pyrotinib dimaleate Alflutinib (Furmonertinib) mesylate EGFR Inhibitor Chrysophanic Acid Norcantharidin WZ8040 Butein Cyasterone Avitinib (Abivertinib) CNX-2006 MTX-211 Naquotinib(ASP8273) Tuxobertinib (BDTX-189) WZ3146 Sunvozertinib (DZD9008) Tyrphostin 9 EAI045 zipalertinib (TAS6417) Almonertinib (HS-10296) AG-18	もっと見る
関連化合物ライブラリー	Kinase Inhibitor Library Tyrosine Kinase Inhibitor Library PI3K/Akt Inhibitor Library Cell Cycle compound library Angiogenesis Related compound Library	もっと見る

シグナル伝達経路

EGFRシグナル伝達経路

EGFR阻害剤の選択性比較

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	活性情報	PMID
VP-2	Growth Inhibition Assay	50 nM	10 d	inhibits proliferation in long-term (10-day) growth inhibition assays	25477325
PC-9/ERc1	Growth Inhibition Assay	50 nM	10 d	inhibits proliferation in long-term (10-day) growth inhibition assays	25477325
PC-9/BRc1	Growth Inhibition Assay	50 nM	10 d	inhibits proliferation in long-term (10-day) growth inhibition assays	25477325
VP-2	Function Assay	50 nM	24 h	induces expression of the proapoptotic BCL-2 family member BIM	25477325
PC-9/ERc1	Function Assay	50 nM	24 h	induces expression of the proapoptotic BCL-2 family member BIM	25477325
PC-9/BRc1	Function Assay	50 nM	24 h	induces expression of the proapoptotic BCL-2 family member BIM	25477325
PC9 GR4	Function Assay	0-10 μM	72 h	inhibits EGFR phosphorylation and downstream signaling	25948633
PC9	Function Assay	0-10 μM	72 h	inhibits WT EGFR at low concentrations	25948633
PC9 GR4	Growth Inhibition Assay	0-10 μM	72 h	inhibits cell growth dose dependently	25948633
BAF3	Function assay		72 h	GI50 = 0.0003 μM	28282122
BAF3	Function assay		72 h	GI50 = 0.0003 μM	28282122
BAF3	Function assay		72 h	GI50 = 0.001 μM	28282122
HCC827	Function assay		72 h	GI50 = 0.001 μM	28282122
PC9	Function assay		72 h	GI50 = 0.002 μM	28282122
BAF3	Function assay		4 h	EC50 = 0.002 μM	28282122
HCC827	Function assay		3 h	IC50 = 0.0025 μM	27433829
H1975	Function assay		3 h	IC50 = 0.0025 μM	27433829
H3255	Function assay		3 h	IC50 = 0.0041 μM	27433829
NCI-H1975	Function assay		72 h	GI50 = 0.005 μM	28282122
PC9	Antiproliferative activity assay		72 h	IC50 = 0.0065 μM	28716641
NCI-H1975	Antiproliferative activity assay		72 h	IC50 = 0.0105 μM	28716641
PC9-DRH	Function assay		2 h	IC50 = 0.013 μM	26756222
BAF3	Function assay		72 h	GI50 = 0.013 μM	28282122
HCC827	Function assay		96 h	EC50 = 0.014 μM	28225269
HCC827	Antiproliferative activity assay		96 h	EC50 = 0.014 μM	28853575
NCI-H1975	Antiproliferative activity assay		96 h	EC50 = 0.014 μM	28853575
NCI-H1975	Function assay		2 h	IC50 = 0.015 μM	26756222
H1975	Function assay		2 h	IC50 = 0.015 μM	26968253
PC9	Function assay		2 h	IC50 = 0.017 μM	26968253
NCI-H1975	Antiproliferative activity assay		72 h	IC50 = 0.019 μM	29466773
NCI-H1975	Function assay		96 h	EC50 = 0.019 μM	28225269
NCI-H1975	Antiproliferative activity assay		96 h	EC50 = 0.019 μM	28603991
NCI-H1975	Antiproliferative activity assay		72 h	IC50 = 0.019 μM	29853340
HCC827	Function assay		2 h	IC50 = 0.023 μM	26756222
NCI-H1975	Antiproliferative activity assay		72 h	IC50 = 0.023 μM	29534926
PC9	Cytotoxicity assay		72 h	GI50 = 0.023 μM	25271963
NCI-H1975	Cytotoxicity assay		72 h	GI50 = 0.024 μM	25271963
HCC827	Antiproliferative activity assay		72 h	IC50 = 0.0254 μM	29576272
HCC827	Antiproliferative activity assay		72 h	IC50 = 0.027 μM	29466773
HCC827	Antiproliferative activity assay		72 h	IC50 = 0.027 μM	29853340
NCI-H1975	Antiproliferative activity assay		72 h	IC50 = 0.03 μM	28033579
H3255	Function assay		72 h	GI50 = 0.033 μM	28282122
H3255	Function assay		2 h	IC50 = 0.036 μM	26756222
NCI-H1975	Antiproliferative activity assay		72 h	IC50 = 0.041 μM	29730192
NCI-H1975	Function assay		1 h	IC50 = 0.041 μM	29534926
BAF3	Function assay		4 h	EC50 = 0.043 μM	28282122
NCI-H1975	Antiproliferative activity assay		72 h	IC50 = 0.0472 μM	29576272
NCI-H1975	Antiproliferative activity assay		72 h	IC50 = 0.052 μM	27131639
PC9	Function assay		2 h	IC50 = 0.056 μM	26756222
NCI-H1975	Cytotoxicity assay		72 h	IC50 = 0.06 μM	29486953
HaCaT	Function assay		3 h	IC50 = 0.0737 μM	27433829
NCI-H1975	Antiproliferative activity assay		72 h	IC50 = 0.13 μM	30429956
A431	Function assay		1 h	IC50 = 0.141 μM	29534926
Calu3	Cytotoxicity assay		72 h	GI50 = 0.264 μM	25271963
Sf9	Function assay		20 mins	IC50 = 0.278 μM	28482151
BAF3	Function assay		72 h	GI50 = 0.3 μM	28282122
BAF3	Function assay		72 h	GI50 = 0.31 μM	28282122
NCI-H460	Antiproliferative activity assay		72 h	IC50 = 0.4159 μM	28716641
LoVo	Function assay		2 h	IC50 = 0.48 μM	26968253
LoVo	Function assay		2 h	IC50 = 0.48 μM	27996267
A549	Antiproliferative activity assay		72 h	IC50 = 0.486 μM	29576272
BAF3	Function assay		72 h	GI50 = 0.5 μM	28282122
A549	Antiproliferative activity assay		72 h	IC50 = 0.53 μM	29466773
A549	Cytotoxicity assay		72 h	IC50 = 0.53 μM	29853340
BAF3	Function assay		72 h	GI50 = 0.55 μM	28282122
BAF3	Function assay		72 h	GI50 = 0.56 μM	28282122
BAF3	Function assay		72 h	GI50 = 0.59 μM	28282122
HT-29	Cytotoxicity assay		72 h	IC50 = 0.65 μM	29486953
A431	Function assay		96 h	EC50 = 0.667 μM	28225269
A431	Antiproliferative activity assay		96 h	EC50 = 0.67 μM	28853575
A431	Antiproliferative activity assay		72 h	IC50 = 0.685 μM	29534926
A431	Antiproliferative activity assay		96 h	EC50 = 0.7 μM	28603991
A549	Cytotoxicity assay		72 h	IC50 = 0.87 μM	29486953
A431	Antiproliferative activity assay		72 h	IC50 = 0.893 μM	27131639
BA/F3	Antiproliferative activity assay		72 h	IC50 = 1 μM	26258521
BAF3	Growth inhibition assay		72 h	GI50 = 1.2 μM	28282122
NCI-H2122	Function assay		72 h	GI50 = 1.2 μM	28282122
A431	Antiproliferative activity assay		72 h	IC50 = 1.24 μM	30429956
A431	Antiproliferative activity assay		72 h	IC50 = 1.26 μM	29730192
A431	Antiproliferative activity assay		72 h	IC50 = 1.604 μM	28033579
A549	Antiproliferative activity assay		96 h	EC50 = 1.83 μM	28853575
CHL	Growth inhibition assay		72 h	GI50 = 2.9 μM	28282122
H1355	Function assay		72 h	GI50 = 3 μM	28282122
H1703	Function assay		72 h	GI50 = 3.5 μM	28282122
A549	Function assay		72 h	GI50 = 3.5 μM	28282122
CHO	Growth inhibition assay		72 h	GI50 = 4.2 μM	28282122
BAF3	Antiproliferative activity assay		72 h	IC50 = 4.61 μM	30429956
BAF3	Antiproliferative activity assay		72 h	IC50 = 5.15 μM	30429956
BEAS2B	Antiproliferative activity assay		72 h	IC50 = 14.9 μM	28716641
NCI-H1975	Function assay		2 h	IC50 = 15 μM	25271963
PC9	Function assay		2 h	IC50 = 17 μM	25271963
LoVo	Function assay		2 h	IC50 = 480 μM	25271963
HCC827	Antiproliferative activity assay		72 h	Antiproliferative activity against human HCC827 cells at 1 uM after 72 hrs by MTT assay relative to control	29576272
BAF3	Function assay		2 h	Inhibition of EGFR T790M/L858R/C797S mutant (unknown origin) expressed in mouse BAF3 cells assessed as reduction in EGF-induced receptor phosphorylation at 1 to 3 uM preincubated for 2 hrs followed by EGF stimulation for 15 mins by Western blot analysis	30429956
BAF3	Function assay		2 h	Inhibition of EGFR 19D/T790M/C797S mutant (unknown origin) expressed in mouse BAF3 cells assessed as reduction in EGF-induced receptor phosphorylation at 1 to 3 uM preincubated for 2 hrs followed by EGF stimulation for 15 mins by Western blot analysis	30429956
Caco2	Function assay		2 h	Efflux ratio of apparent permeability from basolateral side to apical side over apical side to basolateral side over in human Caco2 cells at 5 uM incubated for 2 hrs	28853575
Caco2	Function assay		2 h	Apparent permeability across apical to basolateral side in human Caco2 cells at 5 uM incubated for 2 hrs	28853575
Caco2	Function assay		2 h	Apparent permeability across basolateral to apical side in human Caco2 cells at 5 uM incubated for 2 hrs	28853575
NCI-H1975	Function assay		4 h	Inhibition of EGFR L858R/T790M mutant in human NCI-H1975 cells assessed as reduction in Akt phosphorylation at Thr308/Ser473 site at 1 uM measured after 4 hrs by Western blot analysis	28282122
HCC827	Function assay		4 h	Inhibition of EGFR exon 19 deletion mutant in human HCC827 cells assessed as reduction in Akt phosphorylation at Thr308/Ser473 site at 1 uM measured after 4 hrs by Western blot analysis	28282122
NCI-H1975	Apoptosis assay		48 h	Induction of apoptosis in human NCI-H1975 cells harboring EGFR L858R/T790M mutant assessed as caspase3 cleavage at 1 uM after 48 hrs by immunoblotting	28282122
HCC827	Apoptosis assay		48 h	Induction of apoptosis in human HCC827 cells harboring EGFR exon 19 deletion mutant assessed as caspase-3 cleavage at 1 uM after 48 hrs by immunoblotting	28282122
PC9	Apoptosis assay		48 h	Induction of apoptosis in human PC9 cells harboring EGFR exon 19 deletion mutant assessed as caspase-3 cleavage at 1 uM after 48 hrs by immunoblotting	28282122
H3255	Apoptosis assay		48 h	Induction of apoptosis in human H3255 cells harboring EGFR L858R mutant assessed as caspase-3 cleavage at 1 uM after 48 hrs by immunoblotting	28282122
NCI-H1975	Apoptosis assay		48 h	Induction of apoptosis in human NCI-H1975 cells harboring EGFR L858R/T790M mutant assessed as PARP cleavage at 1 uM after 48 hrs by immunoblotting	28282122
PC9	Apoptosis assay		48 h	Induction of apoptosis in human PC9 cells harboring EGFR exon 19 deletion mutant assessed as PARP cleavage at 1 uM after 48 hrs by immunoblotting	28282122
HCC827	Apoptosis assay		48 h	Induction of apoptosis in human HCC827 cells harboring EGFR exon 19 deletion mutant assessed as PARP cleavage at 1 uM after 48 hrs by immunoblotting	28282122
H3255	Apoptosis assay		48 h	Induction of apoptosis in human H3255 cells harboring EGFR L858R mutant assessed as PARP cleavage at 1 uM after 48 hrs by immunoblotting	28282122
Sf21	Function assay			IC50 = 0.012 μM	27996267
HCC827	Antiproliferative activity assay			IC50 = 0.0616 μM	28426996
NCI-H1975	Antiproliferative activity assay			IC50 = 0.067 μM	28426996
A549	Function assay			IC50 = 0.15 μM	26756222
HEK293	Function assay			IC50 = 0.57 μM	28426996
A431	Antiproliferative activity assay			IC50 = 0.6156 μM	28426996
NCI-H1975	Antitumor activity assay			Antitumor activity against human NCI-H1975 cells harboring EGFR L858R/T970M double mutant xenografted in SCID mouse assessed as tumor growth inhibition at 2.5 mg/kg/day, po qd for 7 days relative to control	25271963
rat hepatocytes	Function assay			Intrinsic clearance in rat hepatocytes measured per 10'6 cells	25271963
human hepatocytes	Function assay			Intrinsic clearance in human hepatocytes measured per 10'6 cells	25271963
NCI-H1975	Antitumor activity assay			Antitumor activity against human NCI-H1975 cells harboring EGFR L858R/T970M double mutant xenografted in SCID mouse assessed as tumor growth inhibition at 5 mg/kg/day, po qd for 7 days relative to control	25271963
NCI-H1975	Function assay			Selectivity index, ratio of IC50 for EGFR T790M/L858R double mutant expressing human NCI-H1975 cells to IC50 for wild type EGFR expressing human A431 cells	29730192
NCI-H1975	Antitumor activity assay			Antitumor activity against EGFR T790M/L858R double mutant expressing human NCI-H1975 cells xenografted in BALB/c athymic nude mouse assessed as tumor growth inhibition at 10 mg/kg, po bid for 21 days	29730192
HCC827	Apoptosis assay			Induction of apoptosis in human HCC827 cells harboring EGFR E746-A750 deletion mutant assessed as early apoptotic cells at 3 uM after 24 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 1.34%)	29466773
HCC827	Apoptosis assay			Induction of apoptosis in human HCC827 cells harboring EGFR E746-A750 deletion mutant assessed as late apoptotic cells at 3 uM after 24 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 27.14%)	29466773
A549	Function assay			Selectivity ratio of IC50 for human A549 cells expressing wild-type EGFR/K-Ras mutant to IC50 for human NCI-H1975 cells expressing EGFR L858R/T790M double mutant	29486953
NCI-H1975	Antitumor activity assay			Antitumor activity against human NCI-H1975 cells xenografted in STOCK-Foxn1nu/Nju nude mouse assessed as inhibition of tumor growth at 20 mg/kg/day, po qd for 14 days relative to untreated control	28395219
A431	Function assay			Selectivity ratio of EC50 for human A431 cells expressing wild type EGFR to EC50 for human NCI-H1975 cells harboring EGFR-L858R/T790M double mutant	28853575
NCI-H1975	Function assay			Selectivity ratio of IC50 for human NCI-H1975 cells harboring EGFR L858R/T790M double mutant to IC50 for human A431 cells harboring wild-type EGFR	28426996
human hepatocytes	Function assay			Intrinsic clearance in human hepatocytes assessed per million cells	28426996
rat hepatocytes	Function assay			Intrinsic clearance in rat hepatocytes assessed per million cells	28426996
A549, NCI-H1975	Function assay			Selectivity ratio of IC50 for EGF-stimulated wild type EGFR in human A549 cells to IC50 for EGFR L858R/T790M double mutant in human NCI-H1975 cells	26756222
A549, PC9	Function assay			Selectivity ratio of IC50 for EGF-stimulated wild type EGFR in human A549 cells to IC50 for EGFR deletion mutant in human PC9 cells	26756222
HCC827	Apoptosis assay			Induction of apoptosis in human HCC827 cells harboring EGFR E746 to A750 deletion mutant assessed as early apoptotic cells at 3 uM after 24 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 1.34 to 1.67%)	29853340
NCI-H1975	Function assay			Inhibition of EGFR L858R/T790M double mutant phosphorylation in EGF-stimulated human NCI-H1975 cells at 1 to 100 nM by Western blot method	29906114
A431	Function assay			Selectivity ratio, ratio IC50 for human A431 cells overexpressing wild-type EGFR to IC50 for human NCI-H1975 cells expressing EGFR T790M/L858R mutant	27131639
PC9	Antitumor activity assay			Antitumor activity against human PC9 cells harboring EGFR exon 19 deletion activating mutant xenografted in SCID mouse assessed as tumor growth inhibition at 10 mg/kg/day, po qd for 7 days relative to control	25271963
A431	Antitumor activity assay			Antitumor activity against human A431 cells xenografted in SCID mouse assessed as tumor growth inhibition at 5 mg/kg/day, po qd for 7 days relative to control	25271963
他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

生物活性

製品説明

特性

Orally bioavailable mutant-selective EGFR inhibitor that has been tested in Phase III clinical trials for treatment of Non-Small Cell Lung Cancer.

Targets

L858R/T790M EGFR ^[1] (LoVo cells)	Exon 19 deletion EGFR ^[1] (LoVo cells)	WT EGFR ^[1] (LoVo cells)
11.44 nM	12.92 nM	493.8 nM

In Vitro
In vitro	AZD9291 shows significantly more potent inhibition of proliferation in mutant EGFR cell lines compared to wild-type in vitro. ^[2]
Kinase Assay	EGFR cellular phosphorylation assay
Kinase Assay	Cells are seeded (10000 cells/well) in growth medium in Corning black, clear- bottomed 384-well plates and incubated at 37°C with 5% CO₂ overnight. Cells are acoustically dosed using an Echo 555, with compounds serially diluted in 100% DMSO. Plates are incubated for a further 2h, then following aspiration of medium, 40μL lx lysis buffer is added to each well. Greiner black high bind 384-well plates are coated with capture antibody and then blocked with 3% BSA. Following removal of block, 15μL of lysate are transferred to the Greiner black high bind 384-well plates and incubated for 2 hours. Following aspiration and washing of the plates with PBS, 20μL, of detection antibody were added and incubated for 2 hours. Following aspiration and washing of the plates with PBS, 20μL of QuantaBlu fluorogenic peroxidase substrate are added and incubated for 1 hour. 20μL QuantaBlu stop solution are added to plates and fluorescence read on an Envision plate reader using Excitation 352nm wavelength and emission 460nm wavelength. The data obtained with each compound is exported into a suitable software package to perform curve fitting analysis. From this data an IC50 value is determined by calculation of the concentration of compound that is required to give a 50% effect.
細胞実験	細胞株	PC9 cells
	濃度	10, 50, & 100 nM
	反応時間	24 h
	実験の流れ	Cells were treated with increasing concentrations of osimertinib for 24h.
実験結果図	Methods	Biomarkers	結果図	PMID
	Western blot	p-EGFR / p-AKT / p-ERK ABCB1		28416483
	Growth inhibition assay	Cell viability		31043587
	Immunofluorescence	Ki67 / γH2AX / p16		29212784

In Vivo
In Vivo	AZD9291(5mg/kg p.o.) causes profound regression of tumors across EGFRm+ (PC9) and EGFRm+/T790M (H1975) tumor models with profound inhibition of EGFR phosphorylation and key downstream signaling pathways such as AKT and ERK in vivo. ^[2]
動物実験	動物モデル	Mice bearing PC9 and H1975 xenograft tumors
	投与量	~5 mg/kg
	投与経路	p.o.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
臨床試験 (data from https://clinicaltrials.gov, updated on 2024-05-22)
NCT06350097	Not yet recruiting	Non-small Cell Lung Cancer	AstraZeneca\|Daiichi Sankyo	May 16 2024	Phase 3
NCT06323148	Not yet recruiting	Lung Cancer\|EGFR Gene Mutation\|Minimal Residual Disease	Fudan University	April 1 2024	Phase 3
NCT05748093	Recruiting	Non-small Cell Lung Cancer	Maastricht University Medical Center	April 1 2024	Phase 4
NCT06206850	Not yet recruiting	Non-squamous NSCLC	Jair Bar M.D. Ph.D.\|Sheba Medical Center	January 2024	Phase 2
NCT06053099	Recruiting	Non Small Cell Lung Cancer\|EGFR Activating Mutation\|EGFR DEL19\|EGFR L858R	Intergroupe Francophone de Cancerologie Thoracique	January 22 2024	Not Applicable
NCT05954871	Recruiting	Colorectal Cancer\|Non-Small Cell Lung Cancer	Genentech Inc.	January 8 2024	Phase 1

参考
[1] Patent. 2013, WO2013014448 A1. [2] Cross, et al. Mol Cancer Ther. 2013, 12, A109. [3] Ali M, et al. Sci Transl Med. 2022 Mar 30;14(638):eabc7480.

参考

化学情報

分子量	499.61	化学式	C₂₈ H₃₃ N₇ O₂
CAS No.	1421373-65-0	SDF	Download Osimertinib (AZD9291) SDFをダウンロードする
Smiles	CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC
保管	3年-20°C粉	溶液の保管冷凍と解凍の繰り返しを避けるため小分けにしてください	1年-80°Cin solvent
保管	3年-20°C粉	溶液の保管冷凍と解凍の繰り返しを避けるため小分けにしてください	１ケ月-20°Cin solvent

In vitro
Batch:

DMSO : 99 mg/mL ( (198.15 mM)；吸湿したDMSOは溶解度を減少させます。新しいDMSOをご使用ください。)

Ethanol : 99 mg/mL

Water : Insoluble

モル濃度計算器

in vivo Batch: Add solvents to the product individually and in order.					投与溶液組成計算機
	Clear solution	5% DMSO 1 95% Corn oil	0.8mg/ml (1.60mM)	Taking the 1 mL working solution as an example, add 50 μL of 16 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.	投与溶液組成計算機
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O	7.5mg/ml (15.01mM)	Taking the 1 mL working solution as an example, add 50 μL of 150 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to make it clear; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5%DMSO 1 Corn oil	5.0mg/ml (10.01mM)	Taking the 1 mL working solution as an example, add 50 μL of 100 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.

実験計算

モル濃度計算器

質量	濃度	体積	分子量
=	×	×

希釈計算器分子量計算器

投与溶液組成計算機(クリア溶液)

ステップ１：実験データを入力してください。（実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します）

投与量 mg/kg 動物平均体重 g 投与体積（動物毎）μL 動物数匹

ステップ２：投与溶媒の組成を入力してください。（ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください）

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

計算結果：

投与溶媒濃度： mg/ml;

DMSOストック溶液調製方法： mg 試薬を μL DMSOに溶解する（濃度 mg/mL, 注：濃度が当該ロットのDMSO溶解度を超える場合はご連絡ください。 )

投与溶媒調製方法：Take μL DMSOストック溶液に μL PEG300，を加え、完全溶解後μL Tween 80，を加えて完全溶解させた後 μL ddH₂O，を加え完全に溶解させます。

投与溶媒調製方法：μL DMSOストック溶液に μL Corn oil，を加え、完全溶解。

注意：１.ストック溶液に沈殿、混濁などがないことをご確認ください；
２.順番通りに溶剤を加えてください。次のステップに進む前に溶液に沈殿、混濁などがないことを確認してから加えてください。ボルテックス、ソニケーション、水浴加熱など物理的な方法で溶解を早めることは可能です。

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須

* 大学・企業名 大学・企業名を記入してください

* 名前 名前を記入してください

* 電子メール 電子メール・アドレスを記入してください 有効なメールアドレスを入力してください

電話番号

* 内容 お問い合わせ内容をご入力ください

よくある質問（FAQ）

質問1:
Can this formulation be used in mice? What are reconstitution instructions for in vivo with mice?

回答
Osimertinib can be used for animal study. The vehicle we suggest is: 5%DMSO+40%PEG300+5%Tween 80+50%ddH2O.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):